US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
WO1994004193A1
(en)
*
|
1992-08-21 |
1994-03-03 |
Enzon, Inc. |
Novel attachment of polyalkylene oxides to bio-effecting substances
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
NZ250375A
(en)
*
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
US5359030A
(en)
*
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
US5478860A
(en)
*
|
1993-06-04 |
1995-12-26 |
Inex Pharmaceuticals Corp. |
Stable microemulsions for hydrophobic compound delivery
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5965566A
(en)
*
|
1993-10-20 |
1999-10-12 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
AU8052194A
(en)
*
|
1993-10-20 |
1995-05-08 |
Enzon, Inc. |
2'- and/or 7- substituted taxoids
|
US5919455A
(en)
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5643575A
(en)
*
|
1993-10-27 |
1997-07-01 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
US5951974A
(en)
*
|
1993-11-10 |
1999-09-14 |
Enzon, Inc. |
Interferon polymer conjugates
|
DK0730470T3
(da)
*
|
1993-11-10 |
2002-06-03 |
Enzon Inc |
Forbedrede interferonpolymerkonjugater
|
US5730990A
(en)
*
|
1994-06-24 |
1998-03-24 |
Enzon, Inc. |
Non-antigenic amine derived polymers and polymer conjugates
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US5738846A
(en)
*
|
1994-11-10 |
1998-04-14 |
Enzon, Inc. |
Interferon polymer conjugates and process for preparing the same
|
US7008624B1
(en)
*
|
1995-02-22 |
2006-03-07 |
Immunex Corporation |
Antagonists of interleukin-15
|
DE19512484A1
(de)
*
|
1995-04-04 |
1996-10-17 |
Bayer Ag |
Kohlenhydratmodifizierte Cytostatika
|
DE19514087A1
(de)
*
|
1995-04-13 |
1996-10-17 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
|
DE741187T1
(de)
*
|
1995-05-05 |
1997-04-30 |
Hoffmann La Roche |
Rekombinante Obesitäts-(OB)-Proteine
|
ZA963530B
(en)
*
|
1995-05-05 |
1996-11-05 |
Hoffmann La Roche |
Recombinant obese (ob) proteins
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
JP2000507917A
(ja)
|
1995-11-02 |
2000-06-27 |
シェーリング コーポレイション |
持続的低用量サイトカイン注入治療
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
TW517067B
(en)
*
|
1996-05-31 |
2003-01-11 |
Hoffmann La Roche |
Interferon conjugates
|
JP2001508783A
(ja)
*
|
1997-01-29 |
2001-07-03 |
ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー |
Peg化法
|
US6321909B1
(en)
|
1997-02-13 |
2001-11-27 |
Sky High, Llc |
System for storing polyethylene glycol solutions
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
JP4108760B2
(ja)
|
1997-02-21 |
2008-06-25 |
ジェネンテック,インコーポレーテッド |
抗体フラグメント−ポリマー複合体およびヒト化抗il−8モノクローナル抗体
|
US5985263A
(en)
*
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US5981709A
(en)
*
|
1997-12-19 |
1999-11-09 |
Enzon, Inc. |
α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
US7005504B2
(en)
*
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
FR2774687B1
(fr)
*
|
1998-02-06 |
2002-03-22 |
Inst Nat Sante Rech Med |
Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
|
US6180096B1
(en)
*
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
DK1421956T3
(da)
*
|
1998-04-28 |
2007-10-01 |
Applied Research Systems |
Polyol-IFN-beta-konjugater
|
TWI277424B
(en)
|
1998-05-15 |
2007-04-01 |
Schering Corp |
Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
AU767131B2
(en)
*
|
1998-06-08 |
2003-10-30 |
F. Hoffmann-La Roche Ag |
Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
|
US6703381B1
(en)
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
EP1656952B1
(en)
|
1998-10-16 |
2013-12-18 |
Biogen Idec MA Inc. |
Polyalkylene glycol conjugates of interferon beta-1A and uses thereof
|
PL200586B1
(pl)
|
1998-10-16 |
2009-01-30 |
Biogen Idec Inc |
Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
|
AU773891C
(en)
|
1998-10-23 |
2005-02-17 |
Kirin-Amgen Inc. |
Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
PE20010027A1
(es)
|
1999-04-08 |
2001-02-05 |
Schering Corp |
Uso de interferon alfa pegilado en pacientes con melanoma
|
PE20010288A1
(es)
|
1999-07-02 |
2001-03-07 |
Hoffmann La Roche |
Derivados de eritropoyetina
|
WO2001005819A1
(en)
*
|
1999-07-15 |
2001-01-25 |
Kuhnil Pharm. Co., Ltd. |
Novel water soluble-cyclosporine conjugated compounds
|
US7230081B1
(en)
|
1999-11-12 |
2007-06-12 |
Maxygen Holdings, Ltd. |
Interferon gamma conjugates
|
CA2390292A1
(en)
|
1999-11-12 |
2001-05-25 |
Maxygen Holdings Ltd. |
Interferon gamma conjugates
|
ATE435033T1
(de)
|
2000-01-10 |
2009-07-15 |
Maxygen Holdings Ltd |
G-csf konjugate
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
IT1317835B1
(it)
*
|
2000-02-15 |
2003-07-15 |
San Raffaele Centro Fond |
Citochine modificate per uso nella terapia del cancro.
|
US7109303B2
(en)
*
|
2000-02-15 |
2006-09-19 |
Fondazione Centro San Raffaele Del Monte Tabor |
Modified cytokines for use in cancer therapy
|
US7309694B2
(en)
*
|
2000-02-15 |
2007-12-18 |
Fondazione Centro San Raffaele Del Monte Tabor |
Modified cytokines for use in cancer therapy
|
US6586398B1
(en)
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
US7208167B2
(en)
*
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
HUP0303854A2
(hu)
*
|
2000-09-08 |
2004-03-01 |
Gryhon Therapeutics, Inc. |
Szintetikus erythropoiesis-stimuláló proteinek
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
US20020065397A1
(en)
*
|
2000-10-12 |
2002-05-30 |
Joseph Roberts |
Protecting therapeutic compositions from host-mediated inactivation
|
BR0207576A
(pt)
|
2001-02-27 |
2004-04-27 |
Maxygen Aps |
Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
|
US7038015B2
(en)
*
|
2001-04-06 |
2006-05-02 |
Maxygen Holdings, Ltd. |
Interferon gamma polypeptide variants
|
US6958388B2
(en)
|
2001-04-06 |
2005-10-25 |
Maxygen, Aps |
Interferon gamma polypeptide variants
|
US6828305B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
*
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
EP1419191B1
(en)
|
2001-08-22 |
2007-10-17 |
Bioartificial Gel Technologies Inc. |
Process for the preparation of activated polyethylene glycols
|
US6913903B2
(en)
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7166571B2
(en)
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7030082B2
(en)
*
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
US7312192B2
(en)
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
UA78726C2
(en)
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
US20040058865A1
(en)
*
|
2001-11-26 |
2004-03-25 |
Danishefsky Samuel J |
Homing peptide multimers, their preparation and uses
|
US6956135B2
(en)
*
|
2001-12-11 |
2005-10-18 |
Sun Bio, Inc. |
Monofunctional polyethylene glycol aldehydes
|
US6916962B2
(en)
*
|
2001-12-11 |
2005-07-12 |
Sun Bio, Inc. |
Monofunctional polyethylene glycol aldehydes
|
KR100488351B1
(ko)
*
|
2001-12-11 |
2005-05-11 |
선바이오(주) |
신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
|
US7041855B2
(en)
*
|
2001-12-11 |
2006-05-09 |
Sun Bio, Inc. |
Monofunctional polyethylene glycol aldehydes
|
KR100888371B1
(ko)
|
2002-01-17 |
2009-03-13 |
동아제약주식회사 |
가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
|
EP1476181B1
(en)
|
2002-01-18 |
2016-03-23 |
Biogen MA Inc. |
Polyalkylene polymer compounds and uses thereof
|
US20030191056A1
(en)
*
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
GB0209893D0
(en)
*
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
GB0209896D0
(en)
*
|
2002-04-30 |
2002-06-05 |
Molmed Spa |
Conjugate
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
UA86744C2
(en)
|
2002-06-21 |
2009-05-25 |
Ново Нордиск Хэлс Кеа Аг |
Pegylated factor vii glycoforms
|
DE14169110T1
(de)
|
2002-06-28 |
2022-05-12 |
Centre National De La Recherche Scientifique -Cnrs- |
Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
|
CA2491178A1
(en)
*
|
2002-07-03 |
2004-01-15 |
Maxygen Holdings Ltd. |
Full-length interferon gamma polypeptide variants
|
CA2490007C
(en)
|
2002-07-19 |
2011-05-24 |
Omeros Corporation |
Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
|
EP1382352A1
(de)
*
|
2002-07-19 |
2004-01-21 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
Bisacyloxypropylcystein-Konjugate und deren Verwendung
|
AU2003258518B2
(en)
*
|
2002-07-24 |
2007-01-18 |
F. Hoffmann-La Roche Ag |
Polyalkylene glycol acid additives
|
WO2004065362A2
(en)
*
|
2002-08-16 |
2004-08-05 |
University Of Massachusetts |
Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
US7217845B2
(en)
*
|
2002-11-25 |
2007-05-15 |
Sun Bio, Inc. |
Bifunctional polyethylene glycol derivatives
|
AU2003303635B2
(en)
*
|
2002-12-26 |
2009-07-23 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of interferon-beta with enhanced biological potency
|
TWI364295B
(en)
*
|
2002-12-26 |
2012-05-21 |
Mountain View Pharmaceuticals |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
US20040176655A1
(en)
*
|
2003-02-05 |
2004-09-09 |
Ayoub Paul Marie |
Methods of preparing branched alkyl aromatic hydrocarbons
|
WO2004084949A2
(en)
*
|
2003-03-20 |
2004-10-07 |
Xencor |
Generating protein pro-drugs using reversible ppg linkages
|
CA2458085A1
(en)
|
2003-03-21 |
2004-09-21 |
F. Hoffmann-La Roche Ag |
Transcriptional activity assay
|
US7429572B2
(en)
|
2003-05-30 |
2008-09-30 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
GB0320638D0
(en)
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
ES2737837T3
(es)
*
|
2003-10-09 |
2020-01-16 |
Ambrx Inc |
Derivados poliméricos
|
DE602004029173D1
(de)
|
2003-10-10 |
2010-10-28 |
Novo Nordisk As |
Il-21-derivate
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
CN1914223B
(zh)
*
|
2004-02-02 |
2012-02-29 |
Ambrx公司 |
经修饰的人类四螺旋束多肽及其用途
|
JP2007519422A
(ja)
|
2004-02-02 |
2007-07-19 |
アンブレツクス・インコーポレイテツド |
修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
|
US7351787B2
(en)
*
|
2004-03-05 |
2008-04-01 |
Bioartificial Gel Technologies, Inc. |
Process for the preparation of activated polyethylene glycols
|
MXPA06013412A
(es)
|
2004-05-19 |
2007-01-23 |
Maxygen Inc |
Polipeptidos de interferon-alfa y conjugados.
|
US20060194726A1
(en)
*
|
2004-05-25 |
2006-08-31 |
Rueger David C |
Methods of treating cartilage defects
|
WO2005123113A2
(en)
*
|
2004-06-14 |
2005-12-29 |
Intermune, Inc. |
Interferon compositions and methods of use thereof
|
MXPA06014684A
(es)
*
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novedosos polipeptidos de enlace antigeno y sus usos.
|
WO2006005058A2
(en)
*
|
2004-06-30 |
2006-01-12 |
Nektar Therapeutics Al, Corporation |
Polymer-factor ix moiety conjugates
|
EP1773400A2
(en)
*
|
2004-07-08 |
2007-04-18 |
Amgen Inc. |
Therapeutic peptides
|
EP2626368B1
(en)
|
2004-07-19 |
2016-12-21 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
AU2005327906B2
(en)
|
2004-07-21 |
2010-05-13 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
JP4971160B2
(ja)
*
|
2004-08-12 |
2012-07-11 |
シェーリング コーポレイション |
安定するpeg化インターフェロン処方物
|
WO2006031725A2
(en)
|
2004-09-14 |
2006-03-23 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
ATE541934T1
(de)
*
|
2004-12-22 |
2012-02-15 |
Ambrx Inc |
Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
|
BRPI0519430A2
(pt)
|
2004-12-22 |
2009-02-10 |
Ambrx Inc |
hormânio do crescimento humano modificado
|
SG161210A1
(en)
*
|
2004-12-22 |
2010-05-27 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
AU2005322019B2
(en)
*
|
2004-12-22 |
2010-08-26 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
ES2434035T3
(es)
|
2004-12-27 |
2013-12-13 |
Baxter International Inc. |
Conjugados de polímero-factor von Willebrand
|
CA2596232A1
(en)
|
2005-01-31 |
2006-08-03 |
Effector Cell Institute |
The use of emip as cancer therapeutics in combination with electron beam irradiation or adjuvant treatment
|
AU2006299901A1
(en)
|
2005-05-18 |
2007-04-19 |
Maxygen, Inc. |
Evolved interferon-alpha polypeptides
|
US20070015701A1
(en)
*
|
2005-06-01 |
2007-01-18 |
Samuel Zalipsky |
Macromolecular conjugates of bone morphogenetic protein-7
|
KR20080026135A
(ko)
*
|
2005-06-03 |
2008-03-24 |
암브룩스, 인코포레이티드 |
개선된 인간 인터페론 분자 및 이의 용도
|
CN101242842A
(zh)
|
2005-06-17 |
2008-08-13 |
诺瓦提斯公司 |
Sanglifehrin在hcv中的用途
|
EP2360170A3
(en)
|
2005-06-17 |
2012-03-28 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
|
WO2007002362A2
(en)
*
|
2005-06-24 |
2007-01-04 |
Duke University |
A direct drug delivery system based on thermally responsive biopolymers
|
MX2008002149A
(es)
|
2005-08-18 |
2008-04-22 |
Ambrx Inc |
Composiciones de arnt y sus usos.
|
US20070123646A1
(en)
*
|
2005-09-13 |
2007-05-31 |
Lele Bhalchandra S |
Protein-polymer conjugates and synthesis thereof
|
EP1776963A1
(en)
|
2005-10-19 |
2007-04-25 |
Gbf-Gesellschaft Für Biotechnologische Forschung Mbh |
Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
|
PT1954710E
(pt)
*
|
2005-11-08 |
2011-06-07 |
Ambrx Inc |
Aceleradores para a modificação de aminoácidos nãonaturais e polipeptídeos de aminoácidos não-naturais
|
EP2339014B1
(en)
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Methods and compositions comprising non-natural amino acids
|
KR101423898B1
(ko)
*
|
2005-12-14 |
2014-07-28 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
|
CA2634034A1
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
EP1985303B1
(en)
|
2006-01-12 |
2012-11-21 |
Kitasato Daiichi Sankyo Vaccine Co., Ltd. |
Oral composition containing Interferon-alpha
|
EP1991577A2
(en)
|
2006-01-31 |
2008-11-19 |
Parkinson, John F. |
Modulation of mdl-1 activity for treatment of inflammatory disease
|
EP1818392B1
(en)
*
|
2006-02-14 |
2010-08-25 |
Genetix Limited |
Cell culture medium
|
CA2647314A1
(en)
*
|
2006-03-31 |
2007-11-08 |
Baxter International Inc. |
Pegylated factor viii
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
JP5167244B2
(ja)
|
2006-04-11 |
2013-03-21 |
ノバルティス アーゲー |
Hcv/hiv阻害剤およびそれらの使用
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
US20090252720A1
(en)
|
2006-05-24 |
2009-10-08 |
Novo Nordisk Health Care Ag |
Prolonged FIX Analogues and Derivatives
|
EP1897557A1
(en)
*
|
2006-09-07 |
2008-03-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of glycolipids as adjuvants
|
EP2069396B1
(en)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
US8420792B2
(en)
*
|
2006-09-08 |
2013-04-16 |
Ambrx, Inc. |
Suppressor tRNA transcription in vertebrate cells
|
NZ574721A
(en)
*
|
2006-09-08 |
2012-02-24 |
Ambrx Inc |
Hybrid suppressor trna for vertebrate cells
|
BRPI0809583B1
(pt)
*
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CA2685596A1
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
AU2008313248B2
(en)
|
2007-10-16 |
2012-04-26 |
Biocon Limited |
An orally administerable solid pharmaceutical composition and a process thereof
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
TWI541020B
(zh)
|
2008-04-17 |
2016-07-11 |
巴克斯歐塔公司 |
生物活性胜肽
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EP2926825A1
(en)
|
2008-06-27 |
2015-10-07 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
NZ591235A
(en)
|
2008-07-23 |
2012-07-27 |
Ambrx Inc |
Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
|
CN101671390B
(zh)
*
|
2008-09-10 |
2012-10-03 |
海南四环心脑血管药物研究院有限公司 |
人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
|
TR201802361T4
(tr)
|
2008-09-26 |
2018-03-21 |
Ambrx Inc |
Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
|
PL2342223T3
(pl)
|
2008-09-26 |
2017-09-29 |
Ambrx, Inc. |
Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
|
EA019295B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Соединения пуриновых нуклеозидов и способ их получения
|
EP2376088B1
(en)
|
2008-12-23 |
2017-02-22 |
Gilead Pharmasset LLC |
6-O-Substituted-2-amino-purine nucleoside phosphoramidates
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
EP2437768B1
(en)
*
|
2009-06-04 |
2016-08-10 |
The University of North Carolina At Chapel Hill |
Compounds and methods for treating bone disorders and controlling weight
|
US20110097302A1
(en)
*
|
2009-07-16 |
2011-04-28 |
Ta Tung Yuan |
Il-1ra-polymer conjugates
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
JP5801807B2
(ja)
*
|
2009-08-14 |
2015-10-28 |
フェーズバイオ ファーマシューティカルズ,インコーポレイテッド |
修飾された血管作動性腸管ペプチド
|
US8475652B2
(en)
|
2009-10-19 |
2013-07-02 |
Jan A. K. Paul |
Method for purification of uncatalyzed natural fuels from metal ions by means of at least one hemeprotein and use of the at least on hemeprotein
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
JP6148013B2
(ja)
|
2010-03-05 |
2017-06-14 |
リグショスピタレト |
補体活性化のキメラ抑制分子
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
JP2013527145A
(ja)
|
2010-03-31 |
2013-06-27 |
ギリード・ファーマセット・エルエルシー |
リン含有活性化剤の立体選択的合成
|
EP2569331A1
(en)
|
2010-05-10 |
2013-03-20 |
Perseid Therapeutics LLC |
Polypeptide inhibitors of vla4
|
EP2585065A1
(en)
|
2010-06-24 |
2013-05-01 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
MY162837A
(en)
|
2010-08-17 |
2017-07-31 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
EP2611928B1
(en)
|
2010-09-03 |
2016-04-27 |
Academia Sinica |
Anti-c-met antibody and methods of use thereof
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
WO2012045704A1
(en)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
New treatments of hepatitis c virus infection
|
EP2624826B1
(en)
|
2010-10-08 |
2018-07-18 |
Novartis AG |
Vitamin e formulations of sulfamide ns3 inhibitors
|
HUE054318T2
(hu)
*
|
2010-11-12 |
2021-08-30 |
Nektar Therapeutics |
IL-2 molekularész konjugátumai és polimer
|
JP6110791B2
(ja)
|
2010-11-30 |
2017-04-05 |
ノバルティス アーゲー |
C型肝炎ウイルス感染症の新規治療
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
US8440309B2
(en)
|
2011-01-31 |
2013-05-14 |
Confluent Surgical, Inc. |
Crosslinked polymers with the crosslinker as therapeutic for sustained release
|
EP2691094A1
(en)
|
2011-03-31 |
2014-02-05 |
Novartis AG |
Alisporivir to treat hepatitis c virus infection
|
RU2013148779A
(ru)
|
2011-04-01 |
2015-05-10 |
Новартис Аг |
Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
|
AU2012241859A1
(en)
|
2011-04-13 |
2013-10-10 |
Debiopharm International Sa |
Treatment of Hepatitis C virus infection with alisporivir
|
US9561262B2
(en)
|
2011-06-06 |
2017-02-07 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
PL2717898T3
(pl)
|
2011-06-10 |
2019-06-28 |
Bioverativ Therapeutics Inc. |
Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
|
CN103930440A
(zh)
|
2011-07-01 |
2014-07-16 |
拜耳知识产权有限责任公司 |
松弛素融合多肽及其用途
|
WO2013045460A1
(en)
|
2011-09-27 |
2013-04-04 |
Novartis Ag |
Alisporivr for treatment of hepatis c virus infection
|
US8767214B2
(en)
|
2011-10-06 |
2014-07-01 |
Nordson Corporation |
Powder flow detection
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
CN104379171A
(zh)
*
|
2012-04-25 |
2015-02-25 |
第一三共株式会社 |
骨修复促进剂
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
US9181343B2
(en)
|
2012-07-19 |
2015-11-10 |
Redwood Bioscience Inc. |
Antibody specific for CD22 and methods of use thereof
|
US9567395B2
(en)
|
2012-08-16 |
2017-02-14 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
EP3584255B1
(en)
|
2012-08-31 |
2022-02-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
CN110818798A
(zh)
|
2012-10-25 |
2020-02-21 |
美国比奥维拉迪维股份有限公司 |
抗补体C1s抗体和其用途
|
EP2914291B1
(en)
|
2012-11-02 |
2022-02-23 |
Bioverativ USA Inc. |
Anti-complement c1s antibodies and uses thereof
|
WO2014080350A1
(en)
|
2012-11-21 |
2014-05-30 |
The Governors Of The University Of Alberta |
Immunomodulatory peptides and methods of use thereof
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
MX370723B
(es)
|
2013-06-10 |
2019-12-20 |
Ipierian Inc |
Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatía.
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
PL3650014T3
(pl)
|
2013-08-27 |
2022-01-31 |
Gilead Pharmasset Llc |
Preparat złożony dwóch związków przeciwwirusowych
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
JP6629201B2
(ja)
|
2013-11-27 |
2020-01-15 |
アイピエリアン,インコーポレイティド |
タウオパチーの処置方法
|
EP3139949B1
(en)
|
2014-05-08 |
2020-07-29 |
Phasebio Pharmaceuticals, Inc. |
Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
|
SI3183264T1
(sl)
|
2014-08-19 |
2021-03-31 |
Biogen Ma Inc. |
Metoda pegilacije
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
JP6824888B2
(ja)
|
2015-02-09 |
2021-02-03 |
フェーズバイオ ファーマシューティカルズ,インコーポレイテッド |
筋肉の疾患および障害を治療するための方法および組成物
|
PT3344654T
(pt)
|
2015-09-02 |
2021-01-26 |
Immutep Sas |
Anticorpos anti-lag-3
|
BR112018009009A8
(pt)
|
2015-11-03 |
2019-02-26 |
Hoffmann La Roche |
terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
|
KR102673420B1
(ko)
|
2016-04-04 |
2024-06-07 |
바이오버라티브 유에스에이 인코포레이티드 |
항-보체 인자 bb 항체 및 이의 용도
|
WO2018087345A1
(en)
|
2016-11-14 |
2018-05-17 |
F. Hoffmann-La Roche Ag |
COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
|
ES2963839T3
(es)
|
2017-02-08 |
2024-04-02 |
Bristol Myers Squibb Co |
Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
|
CA3069321A1
(en)
|
2017-07-11 |
2019-01-17 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
AU2018309166B2
(en)
|
2017-08-03 |
2022-12-08 |
Synthorx, Inc. |
Cytokine conjugates for the treatment of proliferative and infectious diseases
|
HRP20240016T1
(hr)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Konjugati polipeptida interleukina-2 i njihove uporabe
|
CN113366015A
(zh)
|
2018-10-19 |
2021-09-07 |
Ambrx公司 |
白细胞介素-10多肽缀合物、其二聚体及其用途
|
SG11202107354WA
(en)
|
2019-02-06 |
2021-08-30 |
Synthorx Inc |
Il-2 conjugates and methods of use thereof
|
BR112021015832A2
(pt)
|
2019-02-12 |
2022-01-18 |
Ambrx Inc |
Composições que contêm conjugados de anticorpo-agonista de tlr, métodos e usos dos mesmos
|
WO2021183832A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
AU2022249223A1
(en)
|
2021-04-03 |
2023-10-12 |
Ambrx, Inc. |
Anti-her2 antibody-drug conjugates and uses thereof
|